Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018)
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.23.02722 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Atsuo Takashima und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Oxaliplatin, Bevacizumab. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Doublet chemotherapy with fluoropyrimidine (FP) and oxaliplatin (OX) plus bevacizumab (BEV) is a standard regimen for unresectable metastatic colorectal cancer (MCRC). However, the efficacy of adding OX to FP plus BEV (FP + BEV) remains unclear for older patients, a population for whom FP + BEV is standard. We aimed to confirm the superiority of adding OX to FP + BEV for this population. METHODS This open-label, randomized, phase III trial was conducted at 42 institutions in Japan. Patients with unresectable MCRC age 70-74 years with Eastern Cooperative Oncology Group performance status (ECOG-PS) 2 and those 75 years and older with ECOG-PS 0-2 were randomly assigned (1:1) to an FP + BEV arm or an OX addition (FP + BEV + OX) arm. Fluorouracil plus levofolinate calcium or capecitabine was declared before enrollment. The primary end point was progression-free survival (PFS). The study was registered in the Japan Registry of Clinical Trials (identifier: jRCTs031180145). RESULTS Between September 2012 and March 2019, 251 patients were randomly assigned to the FP + BEV arm (n = 125) and the FP + BEV + OX arm (n = 126). The median age was 80 and 79 years in the respective arm. The median PFS was 9.4 months (95% CI, 8.3 to 10.3) in the FP + BEV arm and 10.0 months (9.0 to 11.2) in the FP + BEV + OX arm (hazard ratio [HR], 0.84 [90.5% CI, 0.67 to 1.04]; one-sided P = .086). The median overall survival was 21.3 months (18.7 to 24.3) in the FP + BEV arm and 19.7 months (15.5 to 25.5) in the FP + BEV + OX arm (HR, 1.05 [0.81 to 1.37]). The proportion of any grade ≥3 adverse events was higher in the FP + BEV + OX arm (52% v 69%). There was one treatment-related death in the FP + BEV arm and three in the FP + BEV + OX arm. CONCLUSION No benefit of adding OX to FP + BEV as first-line treatment was demonstrated in older patients with MCRC. FP + BEV is recommended for this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Medical Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
- JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
- Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.
- Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
- Department of Gastroenterological Surgery, Gunma Prefectural Cancer Center, Gunma, Japan.
ORCID-Profile: Atsuo Takashima, Tetsuya Hamaguchi, Junki Mizusawa, Fumio Nagashima, Hitoshi Ojima, Tadamichi Denda, Hideo Baba, Seiji Hasegawa, Toshiki Masuishi, Shunsuke Tsukamoto, Hiroshi Katayama, Kenichi Nakamura, Yukihide Kanemitsu
Zitieren
APA
Takashima, A., Hamaguchi, T., Mizusawa, J., Nagashima, F., Ando, M., Ojima, H., Denda, T., Watanabe, J., Shinozaki, K., Baba, H., Asayama, M., Hasegawa, S., Masuishi, T., Nakata, K., Tsukamoto, S., Katayama, H., Nakamura, K., Fukuda, H., Kanemitsu, Y., …, & Colorectal Cancer Study Group in Japan Clinical Oncology Group (JCOG) (2024). Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018). Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.02722
Vancouver
Takashima A, Hamaguchi T, Mizusawa J, Nagashima F, Ando M, Ojima H, et al. Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018). Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.02722
BibTeX
@article{Takashima2024,
author = {Takashima, Atsuo and Hamaguchi, Tetsuya and Mizusawa, Junki and Nagashima, Fumio and Ando, Masahiko and Ojima, Hitoshi and Denda, Tadamichi and Watanabe, Jun and Shinozaki, Katsunori and Baba, Hideo and Asayama, Masako and Hasegawa, Seiji and Masuishi, Toshiki and Nakata, Ken and Tsukamoto, Shunsuke and Katayama, Hiroshi and Nakamura, Kenichi and Fukuda, Haruhiko and Kanemitsu, Yukihide and Shimada, Yasuhiro and Colorectal Cancer Study Group in Japan Clinical Oncology Group (JCOG), Colorectal Cancer Study Group in Japan Clinical Oncology Group (JCOG)},
title = {Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018)},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.23.02722}
}
EUVIMED